Novavax, Inc.
NVAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.6B
Close$
$24.78
155.5% upside
Current Fair Value
155.5% upsideUndervalued by 155.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.60 Billion |
|---|---|
| Enterprise Value | $1.79 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.72 |
| Beta | 2.44 |
| Outstanding Shares | 164,574,000 |
Return
| Return on Equity | 129.90% |
|---|---|
| Return on Assets | -25.92% |
| Return on Invested Capital | -29.16% |
Valuation & Multiples
| P/E Ratio | -6.38 |
|---|---|
| PEG | 4.25 |
| Price to Sales | 4.85 |
| Price to Book Ratio | -4.85 |
| Enterprise Value to Revenue | 4.33 |
| Enterprise Value to EBIT | -9.83 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | -2.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$52.51 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$74.62 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 121.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.45%▼ 64.28% |
|---|---|
| Total Invested | $150.39M▼ 86.55% |
| Investors Holding | 35▼ 264.00% |
ESG Score
No data
About Novavax, Inc.
749 employees
CEO: Stanley Erck Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxov...